Anti-human CD134 (OX40) (Vonlerolizumab)

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Vonlerolizumab. Vonlerolizumab specifically targets and binds to CD134 (OX40).

CD134, also known as OX40 or TNFRSF4, belongs to the tumor necrosis factor receptor (TNFR) superfamily. It is a protein found on the surface of activated T cells, natural killer (NK) cells, dendritic cells, and other immune cells. CD134 acts as a co-stimulatory molecule, boosting T cell proliferation, survival, and cytokine production when binding to its ligand, OX40L. This interaction plays a critical role in immune responses, rendering CD134 an appealing target for cancer immunotherapy^1-4.

Vonlerolizumab, also known as MOXR0916, is a humanized monoclonal antibody of the IgG1 class, which specifically targets the CD134 (OX40) receptor in the body. Upon binding to this receptor, it acts as an agonist, thereby stimulating the activation and proliferation of T cells as well as other immune cells, and ultimately bolstering the body's antitumor response. Ongoing research focuses on exploring the potential of vonlerolizumab in treating a wide spectrum of solid tumors and hematologic malignancies⁵.

CD134 is expressed on the surface of activated T cells, NK cells, dendritic cells, and other immune cells.

TNFSF4/OX40L/GP34, TRAF2, TRAF3, TRAF5, Human herpesvirus 6B/HHV-6B gQ1:gQ2 proteins

1. Adler AJ, Vella AT. Oncoimmunology. 2013;2(1):e22837.
2. Li M, Zhang Y. Cell Mol Immunol. 2005;2(6):467-471.
3. Baumann R, Yousefi S, Simon D, Russmann S, Mueller C, Simon HU. Eur J Immunol. 2004;34(8):2268-2275.
4. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Clin Cancer Res. 2013;19(5):1044-1053.
5. Kim TW, Burris HA, de Miguel Luken MJ, et al. Clin Cancer Res. 2022;28(16):3452-3463.
6. Vonlerolizumab Humanized Recombinant Monoclonal Antibody (MA5-42105). Accessed August 15, 2024. https://www.thermofisher.com/antibody/product/Vonlerolizumab-Humanized-Antibody-Recombinant-Monoclonal/MA5-42105